Axcella appoints three senior leaders
During his 13 years as an investment banker, Mr. Leggett worked at J.P. Morgan Securities, Healthcare Group and later as a Vice President at Lazard Frères & Company and an Executive Director in the Healthcare Group at UBS Securities.
Most recently, as the Treasurer and Head of Business Development Finance at Purdue Pharma L.P., Mr. Leggett executed five strategic transactions, including the recently announced alliance for the joint U.S. commercialization of Symproic (naldemedine) with Shionogi & Co., Ltd.
Mr. Leggett received his Bachelor of Arts in Economics from Columbia University and earned his Master’s in Business Administration in Finance from The Wharton School.
The company also announces Iman Barilero as senior vice president, chief regulatory science, patient advocacy and pharmacovigilance officer.
Dr. Barilero comes to Axcella with 30 years of multidisciplinary, international drug development and regulatory experience across academia and industry, spanning a broad spectrum of therapeutic areas.
Before joining Axcella, Dr. Barilero served as Vice President, Global Regulatory Development Strategy, Science, Intelligence and Policy at Lundbeck, where she played an instrumental role in the global approval of several product.
Dr. Barilero previously worked in regulatory affairs at Johnson & Johnson and held roles of increasing responsibility at Hoffman-La Roche in regulatory affairs, pharmacovigilance and medical information.
Dr. Barilero received her Pharm.D. from the University of Damascus and both her Master’s degree in Molecular and Cellular Pharmacology and Ph.D. in Pharmacology from the University of Paris VI.
She also recently obtained her certificate in Leadership Transition from INSEAD Business School in Paris.
Veena Warikoo is named as vice president, product development.
Dr. Warikoo has 17 years of experience in process development, manufacturing and organizational management.
Most recently, Dr. Warikoo worked for nearly a decade at Sanofi Genzyme, where she held roles of increasing responsibility in therapeutics development and manufacturing, including overseeing the development of an end-to-end, integrated biomanufacturing platform.
During her career, she has worked on the commercialization teams for several drugs.
Dr. Warikoo obtained her Ph.D. in Microbiology from the University of Oklahoma and completed her postdoctoral training in Environmental Engineering at Stanford University. ■
LATEST MOVES FROM Massachusetts
- DentaQuest appoints Alison Corcoran as CMO
- RXI Pharma names Gerrit Dispersyn chief development officer
- resTORbio appoints Joan Mannick as CMO
- C&W Services appoints Mike Losier as director
- Charles River Associates appoints Robert A. Whitman to board
More inside POST